Skip to main content

Table 2 Clinical characteristics by tertiles of plasma NAMPT and glycemic status in Brazilian cohort

From: Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects

  Subjects without type 2 diabetes p Type 2 diabetes subjects p
  T1 T2 T3   T1 T2 T3  
N 98 106 97   100 92 101  
Plasma NAMPT(ng/ml) 3.06 ± 0.74 5.02 ± 0.56a 8.87 ± 2.92ab <0.0001 3.10 ± 0.73 5.00 ± 0.50a 8.67 ± 2.90ab <0.0001
(0.57 – 4.13) (4.14 – 6.05) (6.08 – 19.92) (0.93 – 4.13) (4.14 – 6.03) (6.08 – 20.18)
Age (y) 57 ± 10 59 ± 11 59 ± 11 0.31 59 ± 9 61 ± 10 64 ± 10a 0.01
Sex (male) 58 58 67 0.32 46 61 51 0.11
BMI (kg/m2) 26.8 ± 4.3 25.6 ± 4.2 25.3 ± 4.4a 0.04c 28.5 ± 5.3 27.5 ± 4.6 28.2 ± 4.5 0.31c
Waist circumference (cm) 97 ± 12 90 ± 14 92 ± 12 0.05c 102 ± 12 98 ± 12 99 ± 12 0.19c
Fasting Plasma Glucose (mmol/l) 5.6 ± 0.6 5.5 ± 0.6 5.4 ± 0.5 0.07 8.6 ± 3.7 8.1 ± 3.0 7.9 ± 2.6 0.38
HbA1c (%) 5.8 ± 0.4 5.9 ± 0.4 5.7 ± 0.4ab 0.004 7.7 ± 1.7 7.6 ± 1.6 7.8 ± 1.8 0.78
LDL cholesterol (mmol/l) 2.77 ± 0.89 2.86 ± 0.93 2.59 ± 0.95 0.05 2.40 ± 0.79 2.58 ± 1.01 2.55 ± 0.92 0.62
HDL cholesterol (mmol/l) 0.98 ± 0.25 1.04 ± 0.28 1.01 ± 0.28 0.45 1.04 ± 0.28 0.98 ± 0.29 1.00 ± 0.30 0.29
Triglycerides (mmol/l) 1.85 ± 1.53 1.54 ± 0.69 1.38 ± 0.68a 0.002 1.96 ± 1.22 1.94 ± 1.09 1.67 ± 0.94a 0.05
Total adiponectin (μg/ml) 8.8 ± 6.1 10.4 ± 6.9 11.2 ± 7.8a 0.006c 8.4 ± 5.5 8.3 ± 8.1 8.5 ± 6.2 0.82c
Arterial hypertension (%) 87 81 87 0.44 96 100 95 0.15
eGFR (ml/min) 87 ± 21 87 ± 25 86 ± 22 0.89 84 ± 24 82 ± 29 84 ± 28 0.56
Prevalence of CAD (%) 77 64 70 0.15 57 67 75 0.02
Antihypertensive medication (%)         
ACEi 50 44 42 0.52 61 71 65 0.31
ARB 12 14 13 0.92 17 10 10 0.23
BB 41 48 40 0.47 57 52 54 0.48
Antidiabetic medication (%)  
MTF -- -- -- -- 46 45 41 0.79
SU -- -- -- -- 27 22 23 0.75
INS -- -- -- -- 22 20 33 0.10
  1. Data expressed as mean ± SD (and range, for plasma NAMPT levels). Statistics for quantitative parameters are ANOVA or ANCOVA with log-transformed data. Tukey Kramer HSD test following ANOVA/ANCOVA: significantly different (p < 0.05) from T1 (a) or T2 (b). Comparison adjusted for age and sex (c). eGFR estimated glomerular filtration rate, UAE urinary albumin excretion rate, ACEi angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, BB beta-blocker MTF metformin, SU sulfonylurea, INS insulin.